KLRK1 and cancer: Several studies have demonstrated that soluble forms of NKG2D-ligands that were derived from cancer cells by either proteolytic shedding (61–63), alternative splicing (64), or exosome secretion (65) can impair NKG2D-mediated cytotoxicity by negatively regulating NKG2D expression or recognition (66).